Your browser doesn't support javascript.
loading
Longitudinal evidence for a relation between depressive symptoms and quality of life in schizophrenia using structural equation modeling.
van Rooijen, Geeske; van Rooijen, Maaike; Maat, Arija; Vermeulen, Jentien M; Meijer, Carin J; Ruhé, Henricus G; de Haan, Lieuwe; Alizadeh, Behrooz Z; Bartels-Velthuis, Agna A; van Beveren, Nico J; Bruggeman, Richard; Cahn, Wiepke; Delespaul, Philippe; Myin-Germeys, Inez; Kahn, Rene S; Schirmbeck, Frederike; Simons, Claudia J P; van Amelsvoort, Therese; van Haren, Neeltje E; van Os, Jim; van Winkel, Ruud.
Afiliación
  • van Rooijen G; Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: g.vanrooijen@amc.uva.nl.
  • van Rooijen M; Verwey-Jonker Instituut, Utrecht, The Netherlands. Electronic address: mvanrooijen@verwey-jonker.nl.
  • Maat A; Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: a.maat-2@umcutrecht.nl.
  • Vermeulen JM; Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands. Electronic address: j.m.vermeulen@amc.uva.nl.
  • Meijer CJ; Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands. Electronic address: c.j.meijer@amc.uva.nl.
  • Ruhé HG; Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands; Department of Psychiatry, Radboud University Nijmegen, Nijmegen, The Netherlands.
  • de Haan L; Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands; Arkin, Institute for Mental Health, Amsterdam, The Netherlands. Electronic address: l.dehaan@amc.uva.nl.
  • Alizadeh BZ; University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Groningen, The Netherlands; University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands. Electronic address: b.z.alizadeh@umcg.nl.
  • Bartels-Velthuis AA; University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Groningen, The Netherlands. Electronic address: a.a.bartels@umcg.nl.
  • van Beveren NJ; Antes Center for Mental Health Care, Rotterdam, The Netherlands; Erasmus MC, Department of Psychiatry, Rotterdam, The Netherlands; Erasmus MC, Department of Neuroscience, Rotterdam, The Netherlands. Electronic address: nico.van.Beveren@deltapsy.nl.
  • Bruggeman R; University of Groningen, University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, Groningen, The Netherlands; University of Groningen, Department of Clinical and Developmental Neuropsychology, Groningen, The Netherlands. Electronic address: r.bruggeman@umcg.nl
  • Cahn W; Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands; Altrecht, General Menthal Health Care, Utrecht, The Netherlands. Electronic address: w.cahn@umcutrecht.nl.
  • Delespaul P; Maastricht University Medical Center, Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht, The Netherlands. Electronic address: ph.delespaul@maastrichtuniversity.nl.
  • Myin-Germeys I; KU Leuven, Department of Neuroscience, Research Group Psychiatry, Center for Contextual Psychiatry, Leuven, Belgium. Electronic address: inez.germeys@kuleuven.be.
  • Kahn RS; Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: r.kahn@umcutrecht.nl.
  • Schirmbeck F; Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands; Arkin, Institute for Mental Health, Amsterdam, The Netherlands. Electronic address: n.f.schirmbeck@amc.uva.nl.
  • Simons CJP; Maastricht University Medical Center, Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht, The Netherlands; GGzE, Institute for Mental Health Care Eindhoven, Eindhoven, The Netherlands. Electronic address: c.simons@maastrichtuniversity.nl.
  • van Amelsvoort T; Maastricht University Medical Center, Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht, The Netherlands. Electronic address: t.vanamelsvoort@maastrichtuniversity.nl.
  • van Haren NE; Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: n.e.m.vanharen@umcutrecht.nl.
  • van Os J; Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands; King's College London, King's Health Partners, Department of Psychosis Studies, Institute of Psychiatry, London, United Kingdom. Electronic address: j.j.vanos-2@umcutrecht.nl.
  • van Winkel R; Maastricht University Medical Center, Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht, The Netherlands; KU Leuven, Department of Neuroscience, Research Group Psychiatry, Center for Contextual Psychiatry, Leuven, Belgium. Electronic address: ruud.vanwink
Schizophr Res ; 208: 82-89, 2019 06.
Article en En | MEDLINE | ID: mdl-31047723
ABSTRACT
Patients diagnosed with schizophrenia often report a low quality of life (QoL). The purpose of this study was to investigate whether we could replicate a cross-sectional model by Alessandrini et al. (2016, n = 271) and whether this model predicts QoL later in life. This model showed strong associations between schizophrenia spectrum symptoms and depressive symptoms on QoL, but lacked follow-up assessment. This model was adapted in the current study and the robustness was investigated by using a longitudinal design in which the association between baseline variables (including IQ, depression, schizophrenia spectrum symptoms as well as social functioning) and QoL during 3-years of follow-up was investigated. We included patients with a non-affective psychotic disorder (n = 744) from a prospective naturalistic cohort-study. In the cross-sectional model, with good measure of fit, both depression as well as social functioning was associated with QoL (direct path coefficient -0.28 and 0.41, respectively). Additionally, the severity of schizophrenia spectrum symptoms was highly associated with social functioning (direct path coefficient -0.70). Importantly, the longitudinal model showed good measures of fit, which strengthens the validity of the initial model and highlights that depression prospectively affect QoL while schizophrenia spectrum symptoms prospectively influence QoL via social functioning. The negative, longitudinal impact of a depression on QoL highlights the need to focus on treatment of this co-morbidity.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trastornos Psicóticos / Calidad de Vida / Esquizofrenia / Depresión / Modelos Biológicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Schizophr Res Asunto de la revista: PSIQUIATRIA Año: 2019 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Trastornos Psicóticos / Calidad de Vida / Esquizofrenia / Depresión / Modelos Biológicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Schizophr Res Asunto de la revista: PSIQUIATRIA Año: 2019 Tipo del documento: Article